Viking Therapeutics Advances Obesity Pipeline with Key Trials and Strategic Hires — Viking Therapeutics, Inc.

Event summary

Viking Therapeutics' Phase 3 VANQUISH-1 and -2 trials for subcutaneous VK2735 in obesity are fully enrolled and advancing.
Oral Phase 3 trial initiation for VK2735 expected in Q4 2026, positioning it as a potential first orally available dual GLP-1/GIP agonist.
VK2735 maintenance dosing study data expected in Q3 2026 to optimize long-term weight management strategies.
Phase 1 study of amylin agonist VK3019 underway, expanding Viking's obesity portfolio.

The big picture

Viking Therapeutics is making significant strides in its obesity pipeline, with multiple clinical trials advancing and strategic hires strengthening its leadership team. The company's focus on developing both oral and injectable formulations for VK2735 could differentiate it in a competitive market. With a strong cash position of $502 million, Viking is well-positioned to continue its aggressive R&D efforts and potentially capture a significant share of the obesity treatment market.

What we're watching

Clinical Trial Progress: The pace at which Viking Therapeutics' Phase 3 trials for VK2735 will deliver results and the potential impact on obesity treatment market.
Market Differentiation: Whether Viking's dual formulation strategy (oral and injectable) for VK2735 can provide a competitive edge in the crowded GLP-1/GIP agonist space.
Pipeline Expansion: How the addition of VK3019 to Viking's portfolio will influence its long-term strategy and market positioning in obesity treatment.